Another study demonstrates that an agonistic monoclonal antibody targeting TREM2, AL002c, promotes microglial proliferation, reduces fibrillar plaques and dystrophic neurites, and alleviates microglial inflammatory response in a mouse AD model (Wang et al., 2020). Here, TREM2 is linked to Alzheimer disease.